CureVac N.V. (CVAC) Establishes Subsidiary to Advance The RNA Printer(R
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Medifast launches Trilivy, replacing its Optavia brand
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
March 1, 2022 7:17 AM ESTThe RNA Printer(R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeuticsCureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer(R)Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH
TBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 1, 2022 / CureVac N.V. (NASDAQ: CVAC), a global biopharmaceutical company... More
